论文部分内容阅读
［目的］探讨重组人粒细胞集落刺激因子对难治性或复发性急性淋巴细胞白血病患者联合化疗的疗效影响。［方法］将８４例病人随机分为治疗组和对照组各４２例。治疗组用米托蒽醌１０ｍｇ／ｍ２静滴，第１～３天，阿糖胞苷１００ｍｇ／ｍ２静滴，第１～５天，随后加用重组人粒细胞集落刺激因子７５μｇ或１５０μｇ。对照组米托蒽醌、阿糖胞苷用法相同，但不用重组人粒细胞集落刺激因子。［结果］治疗组与对照组相比，缩短了白细胞数恢复时间（１２天、２１天），降低了感染发生率（４６．３％、６９．１％），提高了ＣＲ率（５９．９％、３８．１％）。［结论］米托蒽醌、阿糖胞苷随后重组人粒细胞集落刺激因子治疗难治性、复发性急性淋巴细胞白血病，减轻了骨髓抑制程度，降低了感染发生率，显著提高了完全缓解率。
[Objective] To investigate the effect of recombinant human granulocyte colony-stimulating factor on the efficacy of combined chemotherapy for patients with refractory or relapsed acute lymphoblastic leukemia. [Methods] 84 patients were randomly divided into treatment group and control group with 42 cases each. The treatment group was instilled with mitoxantrone 10 mg/m 2 , the first 3 days, cytarabine 100 mg/m 2 infusion, the first 1 to 5 days, followed by the addition of recombinant human granulocyte colony stimulating factor 75 μg or 150 μg. The use of mitoxantrone and cytarabine in the control group was the same, but no recombinant human granulocyte colony-stimulating factor was used. [Results] Compared with the control group, the treatment group shortened the recovery time of white blood cell (12 days, 21 days), reduced the incidence of infection (46.3%, 69.1%), and improved the CR rate (59.9 %, 38.1%). [Conclusion] Mitoxantrone and cytarabine were followed by recombinant human granulocyte colony-stimulating factor in the treatment of refractory and relapsed acute lymphoblastic leukemia, which reduced the degree of myelosuppression, reduced the incidence of infection, and significantly increased the rate of complete remission. .